- 24/7 Wall St.•1 hour ago
A few biotech and pharma companies were on the move Tuesday. A few of the smaller caps made tremendous gains on the day, as the fourth-quarter earnings season is kicking off.
- MarketWatch•4 hours ago
Alcobra Ltd. stock plummeted 42.6% in pre-market trade Tuesday after the company said its ADHD drug failed to meet its primary endpoint in a phase 3 trial. The company is "exceedingly disappointed" ...
- Reuters•4 hours ago
Alcobra Ltd said on Tuesday its experimental attention deficit hyperactivity disorder (ADHD) therapy failed a late-stage study in adult patients and the company's shares plunged about 44 percent in premarket trading. The Israeli drug developer will take a decision on the drug, MDX, after reviewing the full data set, Chief Executive Dr. Yaron Daniely said. MDX did not induce a statistically significant benefit over a placebo in adults with ADHD, a cognitive disorder characterized by poor concentration, hyperactivity and learning difficulties.
ADHD : Summary for Alcobra Ltd. - Ordinary Shares - Yahoo Finance
Alcobra Ltd. (ADHD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.93 x 1300|
|Ask||0.93 x 200|
|Day's Range||0.83 - 1.07|
|52 Week Range||0.83 - 5.75|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.06|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|